Pharma DECODED
Previous edition: 08 May 2024
Share article
Get the full version straight to your inbox.
Exclusive access to our best-in-class data & intelligence
Subscribe now
AstraZeneca to withdraw Covid-19 vaccine globally
Countries such as Australia have already ceased the supply of Vaxzevria, with its use discontinued since March 2023.
AstraZeneca has begun the global withdrawal of its Covid-19 vaccine, Vaxzevria, citing a surplus of updated vaccines designed to combat new virus variants.
The European Medicines Agency (EMA) issued a notice announcing that the vaccine is no longer authorised for use and that its authorisation had been withdrawn at the request of the marketing authorisation holder.
The new development follows the company's voluntary withdrawal of its marketing authorisation for the vaccine in the European Union in March 2024.
The decision aligns with AstraZeneca's statement, as quoted by the Telegraph, that the availability of newer vaccines adapted to target Covid-19 variants, has decreased the demand for Vaxzevria.
AstraZeneca highlighted the vaccine's impact, stating: “According to independent estimates, over 6.5 million lives were saved in the first year of use alone and over three billion doses were supplied globally”.
The company emphasised its role in addressing the global pandemic and expressed its intention to collaborate with regulators and partners to finalise this phase of its contribution.
Countries such as Australia already ceased the supply of Vaxzevria, with its use discontinued in March 2023.
The vaccine's phase-out began in June 2021 due to the availability of new vaccines.
Vaxzevria, previously known as the AstraZeneca Covid vaccine, was administered as two injections into the upper arm muscle, typically three months apart, and authorised for individuals aged 18 and above.
The vaccine employed a modified adenovirus vector to deliver the SARS-CoV-2 spike protein gene, triggering an immune response without causing an infection itself.
Despite its overall safety and efficacy, Vaxzevria was associated with a rare but severe side effect, thrombosis with thrombocytopenia syndrome (TTS), affecting two to three individuals per 100,000 vaccinated.
The World Health Organization's latest vaccine guidance from April 2024 recommends that Covid-19 vaccine formulations should target the JN.1 lineage, which is displacing the existing XBB lineage variants.
Latest news
Vertex reports net profits of $2.69bn in Q1 2024
The increase in revenue was primarily driven by strong product sales of the cystic fibrosis drug Trikafta in ex-US markets.
BioVersys and GSK expand their partnership for TB treatment alpibectir
Alpibectir is currently undergoing a Phase IIa proof-of-concept clinical trial in South Africa, targeting pulmonary TB patients.
Broken String Biosciences teams up with Francis Crick Institute for ALS research
The companies will utilise Broken String’s DNA break mapping platform Induce-seq for ALS research.
Pfizer reports fatality in Phase II DMD gene therapy study
The company paused participant dosing associated with the crossover portion of its Phase III CIFFREO trial.
OCT Europe: AI and RWD can avoid data replication in trials
The Outsourcing in Clinical Trials Europe conference heard how study costs could be reduced by using data from EHRs.
OCT Europe: Mutual investment a better solution than patient centricity
Although it is important to consider the patient when planning trials, ensuring that all parties have a say is a better solution.
Neurogene reports initial data from Rett syndrome gene therapy trial
According to the initial data, NGN-401 was found to be well-tolerated by all three patients dosed.
In our previous edition
Pharma Decoded
BioNTech reports net loss of €315.1m in Q1 2024
07 May 2024
Pharma Decoded
Amgen reports a 22% increase in Q1 2024 net revenues
06 May 2024
Pharma Decoded
Novo Nordisk aims for market domination, boasts $1.5bn obesity sales in Q1
03 May 2024
Newsletters in other sectors
Aerospace, Defence & Security
Automotive
Foodservice
Medical Devices
Travel and Tourism
Search companies, themes, reports, as well as actionable data & insights spanning 22 global industries
Access more premium companies when you subscribe to Explorer